electroCore, Inc.: management transactions · United States · SEC (Form 4)

About electroCore, Inc.

electroCore, Inc. (Nasdaq: ECOR) is a United States-based commercial-stage bioelectronic medicine and wellness company focused on non-invasive neuromodulation. Headquartered in Rockaway, New Jersey, the company was founded in 2005 around the idea that vagus nerve stimulation could provide new treatment pathways for difficult-to-address conditions. Its business model combines prescription medical devices with consumer wellness offerings, giving electroCore a hybrid profile that sits between medtech and specialty consumer health. The company’s core technology is non-invasive vagus nerve stimulation, or nVNS. Its flagship product, gammaCore, is a handheld non-invasive vagus nerve stimulator used in certain regulated medical indications, including pain-related conditions and other label-specific uses depending on market authorization. electroCore also commercializes Quell Fibromyalgia, as well as Truvaga and TAC-STIM, two products positioned for wellness, relaxation, sleep support, and human performance. This product mix allows the company to participate in prescription channels, institutional settings, and increasingly direct-to-consumer demand. From a competitive standpoint, electroCore occupies a specialized niche in portable, non-implantable neuromodulation. The company’s differentiation lies in its non-pharmacological approach, ease of use, and a technology platform that can be deployed in both clinical and consumer settings. At the same time, it operates in a challenging market structure where larger medical device companies, established drug therapies, and reimbursement dynamics can all affect adoption. As a result, the equity story remains closely tied to commercial execution, regulatory milestones, physician uptake, and the ability to convert clinical interest into repeatable revenue. Geographically, electroCore is primarily rooted in the United States, where it maintains its headquarters and operational base, while also building international reach through distributors and selected markets in the UK and continental Europe. Recent business updates have been constructive: in the first quarter of 2026, electroCore reported net sales of $9.6 million, up 43% year over year, and for full-year 2025 the company announced record net sales of $32.0 million. Recent disclosures also pointed to growth in the wellness segment, stronger prescription sales in the United States, and organizational changes in management. For investors, electroCore represents a small-cap healthcare innovator listed on the U.S. Nasdaq market, with a growth thesis that depends on sustained commercial scaling rather than broad product diversification.